TickerTalks
Browse all tickers →
TickerTalks›$HSDT
HSHSDT

Solana Company

$HSDT·$161M·Asset Management·Financial Services
$2.91+0.3%YTD-1.7%1Y-80.9%
Price updated 6m ago
HSHSDT
$HSDTSolana Company
$2.91+0.34%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $HSDT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $HSDT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-09-24

Falling on heavy selling — points lower unless it turns around.

Rebranded from Helius Medical to "Solana Company" at $2.88; day -12%, t12m -82%, and no evident crypto pivot rationale in the pack.

This ticker is a $160M medical-device neuromodulation company (previously Helius Medical) that appears to have rebranded to "Solana Company" — the pack lists it as a medical-device firm but the name suggests a possible crypto-adjacent positioning.

  • 2026 revenue consensus $11.45M with EPS -$1.65; 2027 EPS turns to -$0.02; 2028 $0.08 — a long path to profitability with tiny revenue base.
  • Q2 EPS -$0.38 vs -$0.02 (-1800%); Q1 -$1.30 vs -$0.12 (-983%); Q4 was an anomaly +$4.25 vs -$26.50 (likely gain on debt extinguishment or similar one-off).
  • Sep-21 head-to-head vs Strive (ASST) — a crypto-adjacent asset-management name — reinforces the crypto pivot read; Aug-21 Solana Governance Proposals disclosure suggests genuine DAO integration. Position in 52w range 0.09.

Nov-17 earnings and any explicit strategic-alternatives disclosure are the reads; the setup is a broken medical-device tape overlaid with an unclear crypto-treasury/rebrand narrative — high uncertainty.

What to watch: Nov-17 print, Solana-treasury policy clarification, and any explicit strategic-alternatives 8-K.

On the calendar: 2026-11-17 — Q3 earnings

no x sentimentno position in 52w rangerebrand ambiguity

Read the AI verdict on $HSDT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical device company developing and licensing non-invasive neurostimulation products for neurological wellness.

Industry overviewAI analysisGenerated by AI from underlying data

Where Asset Management sits in its cycle right now — and what that implies for $HSDT.

Asset Management · Financial Services

No material change from last week — yield-seeking institutional capital continues flowing into private credit and infrastructure alternatives; Blackstone, Apollo, and KKR are primary beneficiaries. Innventure (INV) securities fraud class actions remain an idiosyncratic overhang; Pershing Square's US-listed structure broke out on renewed institutional interest.

What this means for $HSDT

Neutral — Solana Company / neurotechnology medical device business; classified in asset management but operates outside institutional AUM or private credit dynamics.

Top industry ETF

$IAIiShares U.S. Broker-Dealers & Securities Exchanges ETF
+0.6%YTD
+4.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-13.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-200%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-16.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
13.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-123%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
95.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 14, 2026$-0.38$-0.02-1800.0%
Q1 2026May 15, 2026$-1.30$-0.12-983.3%
Q4 2025Mar 30, 2026$4.25$-26.50+116.0%
Q3 2025Nov 18, 2025$-32.89$-50.50+34.9%
Next earningsTue, Nov 17·consensus EPS $0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$2.5M+5774.4%97.0%-343%$-0.38$-11.9M
Q1 FY26$3.6M+7289.8%95.0%-48.3%$-1.30$-4.8M
Q4 FY25$5.2M+3339.5%96.6%-170%$4.25$-6.2M
Q3 FY25$697K+1266.7%85.2%-704%$-32.89$-4.0M

Forward consensus

3-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.4M$11.4M – $11.5M-$1.65-$1.67 – -$1.631
FY27$11.0M$10.9M – $11.1M-$0.02-$0.02 – -$0.021
FY28$13.2M$13.1M – $13.3M$0.08$0.08 – $0.081

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+42.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+32.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 40.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.075-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 17 other (12 awards · 2 exempts · 2 others · 1 inkind) in window

See when $HSDT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentSep 15SC 13D/A
3New insider — initial holdingsJul 133
8-KMaterial agreementMay 298-K — Item 1.01: Material agreement
424B5Prospectus supplement (offering)May 29424B5
SC 13D/AActivist amendmentMay 26SC 13D/A
8-KShareholder voteMay 228-K — Item 5.07: Shareholder vote · Item 8.01: Other event
3New insider — initial holdingsMay 223
SC 13D/AActivist amendmentMay 13SC 13D/A
+ 29 other (4 8-Ks · 3 13Gs · 3 earnings 8-Ks · 3 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Is the Options Market Predicting a Spike in Solana Company Stock?zacks.com·4d agoHead to Head Survey: Solana (NASDAQ:HSDT) vs. Strive (NASDAQ:ASST)defenseworld.net·5d agoVoya Financial (NYSE:VOYA) & Solana (NASDAQ:HSDT) Critical Comparisondefenseworld.net·18d agoSolana Company Announces Positions and Votes on first Solana Governance Proposalsglobenewswire.com·35d agoSolana Company (HSDT) Q2 2026 Earnings Call Transcriptseekingalpha.com·42d ago

More in Asset Management

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ASST$CYPH$SATA$PS$INV$OWL$BX$BN
Voices on X · last 7 days

No standout posts about $HSDT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport